Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BREEZE-AD-PEDS phase 3 trial of baricitinib in pediatric moderate-to-severe atopic dermatitis
MOH_2019-06-13_007200Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2018
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of baricitinib in atopic dermatitis (AD) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Superiority of each baricitinib dose versus placebo during the double-blind treatment period and Comparability of pediatric baricitinib exposure to adult exposure. Started Dec 2018; status: recruiting.
02
Drugs
baricitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on MOH_2019-06-13_007200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-06-13_007200.